osteoporosis

Wednesday Bubble: Your bones, your health. The lowdown on bisphosphonates

Posted by Liz on Sep 8, 2010 in bone health, osteoporosis | 0 comments

For decades, physicians have been prescribing a class of medications known as bisphosphonates (e.g. Fosamax, Actonel, Boniva) to preserve bone health in menopausal women and prevent fractures in both men and women with osteoporosis at high-risk for them).  Bisphosphonates are often offered as an alternative to hormone replacement therapy or HRT.

Studies have shown that after age 35, women (and men) start to lose their bone density at a rate of 0.3% to 0.5% a year.  However, as estrogen levels decline through menopause, the rate of bone density loss accelerates. In fact, during the first five years after menopause, women can experience as much as a 30% loss of bone density. What’s more, experts estimate that by the time a woman reaches the age of 50, she has a 40% risk of suffering a fracture due to osteoporosis for the rest of her lifetime.

If you consider these statistics, it seems that using bisphosphonates is a good thing, right?

Well, not so fast. Earlier this year, I wrote a post highlighting reports of jaw bones collapsing among women taking bisphosphonates over a certain period of time. Included within the information were tips from the American Dental Association for protecting your jaw before any major dental procedures. This week, I want to add another facet to the bisphosphonate story, one that is definitely worth considering when weighing the benefits and risks of these drugs:

It is possible that use of oral bisphosphonates may increase the risk for developing cancer of the esophagus by as much as two-fold.

Here’s what you need to know:

• In this particular study, researchers compared over 15,000 men and women who had been diagnosed with esophageal, gastric or colon cancer over the age of 40 to five healthy individuals with similar characteristics. All study participants had been prescribed bisphosphonates at least once, with some receiving more than 10 prescriptions, which would imply that they used the drugs over time (over the 7-1/2 year period of times examined, a majority used bisphosphonates for at three years or more).
• Use of bisphosphonates over three years and having received at least 10 prescriptions was linked to a significant increase in cancer of the esophagus but not gastric or colon cancer.  People who used bisphosphonates for five years or more had twice the risk compared to those who did not. Note that these rates of cancer held regardless of the exact agent used.
• An increased cancer risk remained even after actors for esophageal cancer, such as age, smoking, alcohol and body mass intake, were accounted for.
• This increased risk, may be due, at least partly, to drug side effects that affect the esophagus directly, such as irritation and inflammation of the esophagus (i.e. esophagitis).

Now, mind you, esophageal cancer is extremely rare, affecting roughly 16,000 people in the US in 2010. However, death from esophageal cancer, is high and the disease is often fatal. Moreover, esophageal cancer tends to affect three to four times as many men as women, which is why this latest bit of information is as critical for men as it is for women entering menopause.

One important thing to keep in mind when you consider the risk and benefits of bisphosphonate therapy is that this particular study compared actual cases of these three types of cancer to healthy individuals in the population. Sometimes, the information yielded in these studies is not considered as conclusive as studies that are conducted proactively, and not retroactively. Still, this is not the first time that bisphosphonates have been linked to cancer of the esophagus.

Maintaining bone health and strength as we age, particularly as hormones decline, is critical to our health in the later years. It’s important to make the right decisions now, while we are still relatively young. Flashfree has plenty of posts on bone health and osteoporosis, and I encourage you to peruse them.  When it comes to your bones, it’s not just about ‘use it or lose it,’ but also, the three P’s:

Protection

Proactive

Prepared

Your bones, your health.

Osteoporosis: what’s the 411?

Posted by Liz on Feb 19, 2010 in bone health, osteoporosis | 0 comments

Osteoporosis and low bone mineral density are well-known issues for menopausal women. As women enter the early stages of menopause, their bones lose their ability to retain their mass and manufacture new bone tissue, resulting in bone loss and increasing the risk for osteoporosis and its deleterious effects. What’s more, experts estimate that by the time a woman reaches the age of 50, she has a 40% risk of suffering a fracture due to osteoporosis for the rest of her lifetime. Besides the discomfort, hip fractures in women lead to a loss of mobility, a need for long-term care and even death. No bones about it; osteoporosis is no laughing matter.

Risk factors that contribute to a loss of bone mineral density are varied and include age, genetics, low calcium/vitamin D intake, body weight and menopause status. However, osteoporosis is a mixed bag and there are several underlying conditions that can also contribute to its severity:

• Medications (e.g. heparin, anticonvulsants, progesterone, chemotherapy agents)
• Parathyroid hormone (which regulates  how calcium is used in the body – released in urine, absorbed in diet and stored in bones)
• Calcium imbalance due to excessive calcium excretion, aka “hypercalciuria,” Vitamin D deficiencies

Before I move into the land of boredom, there is a reason why I’m sharing some of the facts about osteoporosis, which BTW are readily available on the National Osteoporosis Foundation website (if you’ve not perused the site, I strongly encourage you to do so!): there is an indication that your practitioner might not be looking for these important secondary causes! Moreover, sometimes they are not even readily apparent.

Writing in the journal Menopause, researchers studying 204 menopausal women say that they’ve discovered that among the various factors that influence a woman’s risk for low bone density, several impact severity:

• Low vitamin D levels (82% of women in this study had below optimal levels)
• Elevated parathyroid hormone levels (35% of women in the study) — (leads to too much calcium in the blood and a loss of calcium from bones)
• Unusually high calcium excretion (20% of women in the study)
• High bone turnover rates (41% of women in the study) — (high bone turnover refers to an increase in  the breakdown, or resorption of bone without a compensation for the repair of bone, leading to compromised strength, thinning, brittleness and fractures)

There are a number of dietary and lifestyle strategies to prevent osteoporosis, including incorporating Vitamin D and calcium supplementation, omega-3 and omega-6 fatty acids into the diet, and increasing physical activity. More recent findings suggest that beer, onions and even flaxseed may be effective (although more research is needed). Meanwhile, if you’ve recently learnt that your bone mineral density is low (or that you’ve actually developed osteoporosis) you need to speak to your practitioner about some of these other markers. Knowledge is power and the more you know, the greater the likelihood that you can start incorporating treatment now to prevent further bone deterioration.

That’s the 411. No bones about it!